![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PAN PLEADS GUILTY, FACES MILLIONS IN FINES
PAN PLEADS GUILTY, FACES MILLIONS IN FINES
November 28, 2005
Drug manufacturer Pan Pharmaceuticals is facing millions of dollars in fines after pleading guilty to 24 charges relating to defective medication. Several people suffered psychotic episodes, hallucinations and blackouts after taking the travel sickness drug Travacalm before it was recalled in early 2003. The manufacturing methods used by Pan resulted in some batches of Travacalm containing too much of an active ingredient, triggering adverse side effects.
Australian Financial Review (http://afr.com/articles/2005/11/28/1133026385107.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct